Art. -Nr.: HY-121275

Benserazide

(Synonyms: Ro 4-4602)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Benserazide is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide is also a PKM2 inhibitor. Benserazide directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide can be used for the study of Parkinson's disease and melanoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.43%
CAS. Nr.: 322-35-0
Formel: C₁₀H₁₅N₃O₅
Molecular Weight:257.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Benserazide Chemical Structure

CAS. Nr.: 322-35-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Benserazide and Levodopa (LD) individually and in combination (Benserazide + LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

SH-SY5Y cells
Concentration:

25 μM
Incubation Time:

0 hour, 12 hours, 24 hours and 168 hours
Result:

Enhanced cell viability, and inhibited the formation of cytotoxic human serum albumin (HSA) aggregates.

In Vivo

Benserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned rats increases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats with 6-hydroxydopamine (6-OHDA) (8 Ag/4 Al)^[1]
Dosage:

5 mg/kg, 10 mg/kg or 50 mg/kg (Pharmacokinetic study)
Administration:

Intraperitoneal injection
Result:

Increased in exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels were significantly prolonged in a dose-dependent fashion. The AADC activity in the denervated striatal tissues showed a significant decreased by 10 mg/kg and 50 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 322-35-0
Appearance Solid
Molecular Weight 257.24
Formel C₁₀H₁₅N₃O₅
Color Light yellow to orange
SMILES

NC(C(NNCC1=CC=C(C(O)=C1O)O)=O)CO
Synonyms

Ro 4-4602
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (7)

All

Sort by:

Journal Impact Factor

CNS Neurosci Ther

Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model. [Abstract]

2023 Oct;29(10):2925-2939. PMID: 37101388
Nutrients

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson's Disease. [Abstract]

2022 Nov 4;14(21):4678. PMID: 36364939
Gene Ther

Targeting serum response factor (SRF) deactivates ΔFosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson's disease. [Abstract]

2024 Nov;31(11-12):614-624. PMID: 39384937
Microbiol Spectr

Neuroprotective effects of hypoactive Akkermansia muciniphila in MPTP-induced mouse models of Parkinson's disease. [Abstract]

2025 Nov 12;13(12):e0337924. PMID: 41223008
SLAS Discov

A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions. [Abstract]

2020 Sep;25(8):895-905. PMID: 32567455
J Stroke Cerebrovasc Dis

Dopamine receptor agonist pramipexole exerts neuroprotection on global cerebral ischemia/reperfusion injury by inhibiting ferroptosis. [Abstract]

2024 Oct 26:108101. PMID: 39490461
Biochem Genet

Amino Acid Metabolism-Related Gene Kynureninase (KYNU) as a Prognostic Predictor and Regulator of Diffuse Large B-Cell Lymphoma. [Abstract]

2025 Feb 11. PMID: 39932613

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (194.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8874 mL

19.4371 mL

38.8742 mL

5 mM

0.7775 mL

3.8874 mL

7.7748 mL

10 mM

0.3887 mL

1.9437 mL

3.8874 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhou Y, et al. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer. 2020 Jul 1;147(1):139-151. [Content Brief]

[2]. Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199(3):149-59. [Content Brief]

[3]. Chandel TI, et al. A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):275-285. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8874 mL	19.4371 mL	38.8742 mL	97.1855 mL
	5 mM	0.7775 mL	3.8874 mL	7.7748 mL	19.4371 mL
	10 mM	0.3887 mL	1.9437 mL	3.8874 mL	9.7186 mL
	15 mM	0.2592 mL	1.2958 mL	2.5916 mL	6.4790 mL
	20 mM	0.1944 mL	0.9719 mL	1.9437 mL	4.8593 mL
	25 mM	0.1555 mL	0.7775 mL	1.5550 mL	3.8874 mL
	30 mM	0.1296 mL	0.6479 mL	1.2958 mL	3.2395 mL
	40 mM	0.0972 mL	0.4859 mL	0.9719 mL	2.4296 mL
	50 mM	0.0777 mL	0.3887 mL	0.7775 mL	1.9437 mL
	60 mM	0.0648 mL	0.3240 mL	0.6479 mL	1.6198 mL
	80 mM	0.0486 mL	0.2430 mL	0.4859 mL	1.2148 mL
	100 mM	0.0389 mL	0.1944 mL	0.3887 mL	0.9719 mL

Keywords

Benserazide

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Benserazide

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Glycolysis Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Benserazide

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Benserazide

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Glycolysis Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Benserazide

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Benserazide Related Classifications

HY-121275 Related Classifications